AAPC of ASMR and age-standardized DALYs for cardiovascular diseases attributable to secondhand smoke in countries with increasing trends. by Juan Dong (342384)

Subjects:

Cortisol and prolactin concentration in non-pregnant women. by Francois Kiemde (5369657)

Subjects:

PA triggers autophagy in osteosarcoma cells. by Zeyu Zhan (22305085)

Subjects:

ASMR and age-standardized DALYs for cardiovascular diseases attributable to secondhand smoke, 1990–2019. by Juan Dong (342384)

Subjects:

S1 Data - by Francois Kiemde (5369657)

Subjects:

Interplay or correlation of cortisol on prolactin during pregnancy. by Francois Kiemde (5369657)

Subjects:

Molecular Docking Analysis of PA with its core target. by Zeyu Zhan (22305085)

Subjects:

Dynamics of cortisol levels measured in pregnant women during pregnancy determined at different ANC visits. by Francois Kiemde (5369657)

Subjects:

Cortisol and prolactin concentration in peripheral blood and umbilical cord blood at delivery. by Francois Kiemde (5369657)

Subjects:

PA-induced apoptosis in osteosarcoma cells. by Zeyu Zhan (22305085)

Subjects:

PA inhibits the proliferation of osteosarcoma cells. by Zeyu Zhan (22305085)

Subjects:

Malaria infection by gestation and gestational age. by Francois Kiemde (5369657)

Subjects:

GO and KEGG analysis results of PA against osteosarcoma. by Zeyu Zhan (22305085)

Subjects:

Potential targets and PPI networks of PA against osteosarcoma. by Zeyu Zhan (22305085)

Subjects:

Interplay or correlation of prolactin on cortisol during pregnancy. by Francois Kiemde (5369657)

Subjects:

Characteristic of study population. by Francois Kiemde (5369657)

Subjects:

Potential mechanism of anti-osteosarcoma activity of PA. by Zeyu Zhan (22305085)

Subjects:

Dynamic of prolactin in pregnant women during pregnancy. by Francois Kiemde (5369657)

Subjects:

Table1_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.docx by Qiong Jie (13270095)

“…The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …”

Image2_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.TIF by Qiong Jie (13270095)

“…The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …”